Takeda Announces Candidates for New Directors after the Transition  to a Company with Audit and Supervisory

Osaka, Japan, May 10, 2016 --- Takeda Pharmaceutical Company Limited (TSE 4502) today announced that it has decided the candidates for new Directors which will be proposed to the 140th Ordinary General Meeting of Shareholders on June 29, 2016. Takeda previously announced to change its corporate governance system to a Company with Audit and Supervisory if the transition is approved by the shareholders' meeting. The candidates are as follows;

1. Candidates for Non-Audit and Supervisory Committee Directors
Name
Category
Current Role
Yasuchika Hasegawa
Internal
Existing
Director, Chairman of the Board
Christophe Weber
Internal
Existing
Representative Director,
President & Chief Executive Officer
Shinji Honda
Internal
Existing
Senior Managing Director, Corporate Strategy Officer
Masato Iwasaki
Internal
Existing
Director, President, Japan Pharma Business Unit
Andrew Plump
Internal
Existing
Director, Chief Medical & Scientific Officer
Fumio Sudo
Outside
Existing
Outside Director
Masahiro Sakane
Outside
Existing
Outside Director
Michel Orsinger
Outside
New
(Former head of Global Orthopedics Group, Depuy Synthes Companies, Johnson & Johnson)
Toshiyuki Shiga
Outside
New
(Vice- Chairman, Nissan Motor Co., Ltd.)
Emiko Higashi
Outside
New
(Managing Director, Tomon Partners, LLC)
Yoshiaki Fujimori
Outside
New
(Director, Representative Executive Officer, President and CEO, LIXIL Group Corporation)

2. Candidates for Audit and Supervisory Committee Directors
Name
Category
Current Role
Yasuhiko Yamanaka
Internal
New
Corporate Auditor
Shiro Kuniya
Outside
New
Outside Corporate Auditor
Koji Hatsukawa
Outside
New
(Certified Public Accountant)
Jean-Luc Butel
Outside
New
(Global Healthcare Advisor, President, K8 Global Pte. Ltd.)

 

Media Contact
Tsuyoshi Tada
Tel: +81-3-3278-2417

 

###